Home > Signal Pathway > Angiogenesis > VEGFR

VEGFR


VEGF receptors are receptors for vascular endothelial growth factor (VEGF).  There are three main subtypes of VEGFR, numbered 1, 2 and 3. Also, they may be membrane-bound (mbVEGFR) or soluble (sVEGFR), depending on alternative splicing.Vascular endothelial growth factor (VEGF) is an important signaling protein involved in both vasculogenesis (the formation of the circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). In vitro, VEGF has been shown to stimulate endothelial cell mitogenesis and cell migration. VEGF also enhances microvascular permeability and is sometimes referred to as vascular permeability factor.

  • Sorafenib EY0017

    Sorafenib (BAY 43-9006), an orally active multi-kinase inhibitor, targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Sorafenib是Raf-1, B-Raf和VEGFR-2等的多重激酶抑制剂，IC50分别为6 nM, 22 nM和90 nM。

    More

  • Linifanib EY1828

    Linifanib是一种新型，有效，ATP竞争性VEGFR/PDGFR抑制剂，同时抑制KDR， CSF-1R， Flt-1/3和PDGFRβ，其IC50分别为4 nM， 3 nM， 3 nM/4 nM和66 nM ，对具有突变激酶依赖性的癌细胞（即FLT3）最有效。

    More

  • Cediranib EY1586

    Cediranib 是VEGFR(KDR)高活性抑制剂，IC50为1000倍。

    More

  • Telatinib EY1545

    Telatinib是VEGFR2/3, c-Kit和PDGFRα有效抑制剂，IC50值分别为6nM/4nM, 1nM和15nM。

    More

  • SKLB1002 EY1441

    SKLB1002 是一种与ATP竞争的强效VEGFR2抑制剂，其IC50 为32 nM。

    More

  • Sorafenib EY0017

    Sorafenib (BAY 43-9006), an orally active multi-kinase inhibitor, targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Sorafenib是Raf-1, B-Raf和VEGFR-2等的多重激酶抑制剂，IC50分别为6 nM, 22 nM和90 nM。

    More

  • Linifanib EY1828

    Linifanib是一种新型，有效，ATP竞争性VEGFR/PDGFR抑制剂，同时抑制KDR， CSF-1R， Flt-1/3和PDGFRβ，其IC50分别为4 nM， 3 nM， 3 nM/4 nM和66 nM ，对具有突变激酶依赖性的癌细胞（即FLT3）最有效。

    More

  • Cediranib EY1586

    Cediranib 是VEGFR(KDR)高活性抑制剂，IC50为1000倍。

    More

  • Telatinib EY1545

    Telatinib是VEGFR2/3, c-Kit和PDGFRα有效抑制剂，IC50值分别为6nM/4nM, 1nM和15nM。

    More

  • SKLB1002 EY1441

    SKLB1002 是一种与ATP竞争的强效VEGFR2抑制剂，其IC50 为32 nM。

    More
    • Current page6, Total Pages8, Total Record38 First Prev 45678 Next Last Goto
More